Abstract
Peroxisome proliferator activated receptor-γ (PPARγ) ligands increase nitric oxide (NO) production and reduce systemic blood pressure. Asymmetric dimethylarginine (ADMA) is an endogenous nitric oxide synthase (NOS) inhibitor degraded by the enzyme dimethylarginine dimethylaminohydrolase (DDAH), which has two isoforms, DDAH-I and -II. In order to elucidate the mechanism whereby PPARγ ligands affect NO metabolism, their effects on the DDAH-ADMA pathway were investigated. Six-week-old male Wister-Kyoto rats (WKY) and spontaneously hypertensive rats (SHR) were maintained with or without pioglitazone (PIO), a PPARγ ligand. After 4 weeks, serum ADMA levels and urinary daily NO excretion were analyzed. Tissue DDAH expression was examined by real-time polymerase chain reaction (PCR), immunoblotting, and immunohistochemistry. The results showed that PIO decreased serum ADMA and increased urinary NO excretion in both WKY and SHR. Also in both strains, the expression level of DDAH-II in the kidney was increased at transcriptional levels, although the DDAH-I level was unaffected. PIO lowered blood pressure in SHR, but not in WKY. We also demonstrated that PIO induced DDAH-II protein expression in Marbin-Dubin Canine Kidney (MDCK) cells, a renal tubular cell line. In conclusion, a PPARγ ligand was here found to increase NO production partly by upregulating tissue DDAH-II expression and decreasing systemic ADMA levels. This mechanism constitutes a direct action on renal tubular cells, but is less likely to be responsible for the blood pressure-lowering effects of PPARγ ligands. Since ADMA is one of the risk factors for cardiovascular events, this study provides compelling evidence that PPARγ ligands have the potential for reducing cardiovascular risks.
Similar content being viewed by others
Article PDF
References
Cooke JP, Dzau VJ : Derangements of the nitric oxide synthase pathway, L-arginine, and cardiovascular diseases. Circulation 1997; 96: 379–382.
Naruse K, Shimizu K, Muramatsu M, et al: Long-term inhibition of NO synthesis promotes atherosclerosis in the hypercholesterolemic rabbit thoracic aorta. PGH2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler Thromb 1994; 14: 746–752.
Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A : Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 2000; 101: 948–954.
Boger RH, Bode-Boger SM, Thiele W, Junker W, Alexander K, Frolich JC : Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 1997; 95: 2068–2074.
Fujiwara N, Osanai T, Kamada T, Katoh T, Takahashi K, Okumura K : Study on the relationship between plasma nitrite and nitrate level and salt sensitivity in human hypertension: modulation of nitric oxide synthesis by salt intake. Circulation 2000; 101: 856–861.
Surdacki A, Nowicki M, Sandmann J, et al: Reduced urinary excretion of nitric oxide metabolites and increased plasma levels of asymmetric dimethylarginine in men with essential hypertension. J Cardiovasc Pharmacol 1999; 33: 652–658.
Cooke JP : Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000; 20: 2032–2037.
Chan NN, Chan JC : Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 2002; 45: 1609–1616.
MacAllister RJ, Parry H, Kimoto M, et al: Regulation of nitric oxide synthesis by dimethylarginine dimethylaminohydrolase. Br J Pharmacol 1996; 119: 1533–1540.
Cook S, Hugli O, Egli M, et al: Partial gene deletion of endothelial nitric oxide synthase predisposes to exaggerated high-fat diet–induced insulin resistance and arterial hypertension. Diabetes 2004; 53: 2067–2072.
Kathir K, Adams MR : Endothelial dysfunction as a predictor of acute coronary syndromes. Semin Vasc Med 2003; 3: 355–362.
Barbier O, Torra IP, Duguay Y, et al: Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 2002; 22: 717–726.
Calnek DS, Mazzella L, Roser S, Roman J, Hart CM : Peroxisome proliferator-activated receptor gamma ligands increase release of nitric oxide from endothelial cells. Arterioscler Thromb Vasc Biol 2003; 23: 52–57.
Dobrian AD, Schriver SD, Khraibi AA, Prewitt RL : Pioglitazone prevents hypertension and reduces oxidative stress in diet-induced obesity. Hypertension 2004; 43: 48–56.
Stuhlinger MC, Abbasi F, Chu JW, et al: Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420–1426.
Jones LC, Tran CT, Leiper JM, Hingorani AD, Vallance P : Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun 2003; 310: 836–843.
Vester B, Rasmussen K : High performance liquid chromatogrrraphy method for rapid and accurate determination of homocysteine in plasma and serum. Eur J Clin Chem Clin Biochem 1991; 29: 549–554.
Matsuda H, Hayashi K, Arakawa K, et al: Zonal heterogeneity in action of angiotensin-converting enzyme inhibitor on renal microcirculation: role of intrarenal bradykinin. J Am Soc Nephrol 1999; 10: 2272–2282.
Ohta K, Araki N, Shibata M, et al: A novel in vivo assay system for consecutive measurement of brain nitric oxide production combined with the microdialysis technique. Neurosci Lett 1994; 176: 165–168.
Wakino S, Kintscher U, Kim S, Yin F, Hsueh WA, Law RE : Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in vascular smooth muscle cells. J Biol Chem 2000; 275: 22435–22441.
Chen C, Hosokawa H, Bumbalo LM, Leahy JL : Mechanism of compensatory hyperinsulinemia in normoglycemic insulin-resistant spontaneously hypertensive rats. Augmented enzymatic activity of glucokinase in beta-cells. J Clin Invest 1994; 94: 399–404.
Swislocki AL, LaPier TL, Khuu DT, Fann KY, Tait M, Rodnick KJ : Metabolic, hemodynamic, and cardiac effects of captopril in young, spontaneously hypertensive rats. Am J Hypertens 1999; 12: 581–589.
Ishikawa J, Mitani H, Bandoh T, Kimura M, Totsuka T, Hayashi S : Hypoglycemic and hypotensive effects of 6-cyclohexyl-2′-O-methyl-adenosine, an adenosine A1 receptor agonist, in spontaneously hypertensive rat complicated with hyperglycemia. Diabetes Res Clin Pract 1998; 39: 3–9.
Racasan S, Joles JA, Boer P, Koomans HA, Braam B : NO dependency of RBF and autoregulation in the spontaneously hypertensive rat. Am J Physiol Renal Physiol 2003; 285: F105–F112.
Vaziri ND, Ni Z, Oveisi F : Upregulation of renal and vascular nitric oxide synthase in young spontaneously hypertensive rats. Hypertension 1998; 31: 1248–1254.
Wakino S, Hayashi K, Kanda T, et al: PPARγ ligands inhibit Rho/Rho kinase pathway by inducing protein tyrosine phosphatase, SHP-2.-Possible role in anti-hypertensive effects of PPARγ ligands. Circ Res 2004; 95: e45–e55.
Achan V, Broadhead M, Malaki M, et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003; 23: 1455–1459.
Matsuoka H, Itoh S, Kimoto M, et al: Asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in experimental hypertension. Hypertension 1997; 29: 242–247.
Fernandez AP, Serrano J, Castro S, et al: Distribution of nitric oxide synthases and nitrotyrosine in the kidney of spontaneously hypertensive rats. J Hypertens 2003; 21: 2375–2388.
Vaziri ND, Wang XQ, Ni Z, Kivlighn S, Shahinfar S : Effects of aging and AT-1 receptor blockade on NO synthase expression and renal function in SHR. Biochim Biophys Acta 2002; 1592: 153–161.
Fujiwara K, Hayashi K, Matsuda H, et al: Altered pressure-natriuresis in obese Zucker rats. Hypertension 1999; 33: 1470–1475.
Sato K, Sugawara A, Kudo M, Uruno A, Ito S, Takeuchi K : Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertens Res 2004; 27: 417–425.
Boger RH, Sydow K, Borlak J, et al: LDL cholesterol upregulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ Res 2000; 87: 99–105.
Ueda S, Kato S, Matsuoka H, et al: Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res 2003; 92: 226–233.
Achan V, Tran CT, Arrigoni F, Whitley GS, Leiper JM, Vallance P : all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res 2002; 90: 764–769.
Yamagishi T, Saito Y, Nakamura T, et al: Troglitazone improves endothelial function and augments renal klotho mRNA expression in Otsuka Long-Evans Tokushima Fatty (OLETF) rats with multiple atherogenic risk factors. Hypertens Res 2001; 24: 705–709.
Diep QN, El Mabrouk M, Cohn JS, et al: Structure, endothelial function, cell growth, and inflammation in blood vessels of angiotensin II-infused rats: role of peroxisome proliferator-activated receptor-gamma. Circulation 2002; 105: 2296–2302.
Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC : Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 1996; 219: 598–603.
Boger RH, Bode-Boger SM, Szuba A, et al: Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998; 98: 1842–1847.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wakino, S., Hayashi, K., Tatematsu, S. et al. Pioglitazone Lowers Systemic Asymmetric Dimethylarginine by Inducing Dimethylarginine Dimethylaminohydrolase in Rats. Hypertens Res 28, 255–262 (2005). https://doi.org/10.1291/hypres.28.255
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.28.255
Keywords
This article is cited by
-
A functional variant of the dimethylarginine dimethylaminohydrolase-2 gene is associated with myocardial infarction in type 2 diabetic patients
Cardiovascular Diabetology (2019)
-
Treatment with combination of pioglitazone and glimepiride decreases levels of chemerin and asymmetric dimethylarginine (ADMA) in obese type 2 diabetic patients
International Journal of Diabetes in Developing Countries (2019)
-
Serum trans fatty acids, asymmetric dimethylarginine and risk of acute myocardial infarction and mortality in patients with suspected coronary heart disease: a prospective cohort study
Lipids in Health and Disease (2016)
-
Calycosin and formononetin from astragalus root enhance dimethylarginine dimethylaminohydrolase 2 and nitric oxide synthase expressions in Madin Darby Canine Kidney II cells
Journal of Natural Medicines (2013)
-
Mechanisms of disease: pulmonary arterial hypertension
Nature Reviews Cardiology (2011)